CN1305849C - Method for preparing 3-methylamino piperidine and its salt - Google Patents
Method for preparing 3-methylamino piperidine and its salt Download PDFInfo
- Publication number
- CN1305849C CN1305849C CNB200410065966XA CN200410065966A CN1305849C CN 1305849 C CN1305849 C CN 1305849C CN B200410065966X A CNB200410065966X A CN B200410065966XA CN 200410065966 A CN200410065966 A CN 200410065966A CN 1305849 C CN1305849 C CN 1305849C
- Authority
- CN
- China
- Prior art keywords
- compound
- formula
- preparation
- reaction
- obtaining
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Landscapes
- Hydrogenated Pyridines (AREA)
Abstract
本发明涉及3-甲氨基哌啶(I)及其盐的制备方法。其特征在于:以3-氨基吡啶为起始原料通过甲基化反应制得3-甲氨基吡啶,3-甲氨基吡啶在金属钠-醇体系中还原得到3-甲氨基哌啶。3-甲氨基哌啶再和各种酸结合得到其盐。
The present invention relates to the preparation method of 3-methylaminopiperidine (I) and its salt. It is characterized in that: 3-methylaminopyridine is prepared through methylation reaction with 3-aminopyridine as the starting material, and 3-methylaminopyridine is reduced in metal sodium-alcohol system to obtain 3-methylaminopiperidine. 3-Methylaminopiperidine is combined with various acids to obtain its salts.
Description
技术领域technical field
本发明涉及如式(I)所示化合物3-甲氨基哌啶及其盐的制备方法。The present invention relates to the preparation method of the compound 3-methylaminopiperidine represented by formula (I) and salts thereof.
背景技术Background technique
巴洛沙星(Balofloxacin)系由日本中外制药株式会社与韩国Choongwae公司共同开发的氟喹诺酮类抗菌药,于2002年末首次在韩国上市,药用为二水合物[药学进展,2003,27(3):190-193]。本品对耐甲氧西林金葡菌等G+菌的体外活性明显优于环丙沙星(Ciprofloxacin)或氧氟沙星(Ofloxacin),与托氟沙星(Tosufloxacin)和司帕沙星(Sparfloxacin)类似[Nippon Kagaku Ryoho Gakkai Zasshi,1995,43(S-5):1-9],且光毒性低[AntimicrobAgents Chemother,1993,37(10):2217-2223],临床用于治疗由细菌引起的各系统感染。3-甲氨基哌啶是合成巴洛沙星的关键中间体,有关3-甲氨基哌啶的合成方法文献检索到2004年11月份,发现中国医学科学院、中国协和医科大学医药生物技术研究所的研究人员对3-甲氨基哌啶的合成进行了报道[中国医药工业杂志,2004,35(7):385-388],他们以γ-丁内酯为起始原料经八步反应得到产品,总收率11.5%,其间使用了贵金属催化剂PtO2,成本很高。Balofloxacin (Balofloxacin) is a fluoroquinolone antibacterial drug jointly developed by Chugai Pharmaceutical Co., Ltd. of Japan and Choongwae Company of Korea. It was first listed in South Korea at the end of 2002. ): 190-193]. The in vitro activity of this product against G+ bacteria such as methicillin-resistant S. ) similar to [Nippon Kagaku Ryoho Gakkai Zasshi, 1995, 43 (S-5): 1-9], and low phototoxicity [AntimicrobAgents Chemother, 1993, 37 (10): 2217-2223], clinically used to treat system infections. 3-Methylaminopiperidine is the key intermediate for the synthesis of baloxacin. The literature search for the synthesis method of 3-methylaminopiperidine was found in November 2004. The researchers reported the synthesis of 3-methylaminopiperidine [Chinese Journal of Pharmaceutical Industry, 2004, 35(7): 385-388]. They used γ-butyrolactone as the starting material to obtain the product through eight steps of reaction, The total yield is 11.5%, during which noble metal catalyst PtO 2 is used, and the cost is very high.
发明内容Contents of the invention
本发明的目的是提供一种制备3-甲氨基哌啶及其盐的简易合成方法。该方法合成路线短,原料价廉易得,适宜工业化生产。The purpose of the present invention is to provide a kind of simple and easy synthetic method for preparing 3-methylaminopiperidine and salt thereof. The method has short synthesis route, cheap and easy-to-obtain raw materials, and is suitable for industrial production.
本发明的目的可以通过以下措施来达到:The object of the present invention can be achieved through the following measures:
3-甲氨基哌啶的合成路线如下:The synthetic route of 3-methylaminopiperidine is as follows:
其中,R1为(C1~C2)烷基,R2为(C1~C3烷基,R3为(C2~C5)烷基,M为金属Na或金属K。Wherein, R 1 is (C 1 -C 2 ) alkyl, R 2 is (C 1 -C 3 ) alkyl, R 3 is (C 2 -C 5 ) alkyl, and M is metal Na or metal K.
具体操作步骤为:The specific operation steps are:
(1)以3-氨基吡啶为起始原料,和原甲酸酯类试剂反应,得到式II化合物(1) With 3-aminopyridine as the starting material, react with orthoformate reagents to obtain the compound of formula II
(2)式II化合物在醇溶液中,用硼氢化物还原得到式III化合物(2) Formula II compound is in alcoholic solution, obtains formula III compound with borohydride reduction
(3)式III化合物在金属钠-醇体系中还原制得式I化合物(3) compound of formula III is reduced in metal sodium-alcohol system to prepare compound of formula I
(4)式I化合物和各种酸反应得到式I化合物的各种盐。(4) reacting the compound of formula I with various acids to obtain various salts of the compound of formula I.
得到式II化合物的反应中,原甲酸酯类试剂为原甲酸三甲酯、原甲酸三乙酯。优选原甲酸三乙酯。In the reaction to obtain the compound of formula II, the orthoformate reagents are trimethyl orthoformate and triethyl orthoformate. Triethyl orthoformate is preferred.
得到式II化合物的反应中,3-氨基吡啶与原甲酸酯的摩尔比范围为1∶1.5~10。优选为1∶4~7。In the reaction to obtain the compound of formula II, the molar ratio of 3-aminopyridine to orthoformate ranges from 1:1.5 to 10. Preferably it is 1:4-7.
得到式II化合物的反应中,反应在回流下进行。In the reaction to obtain the compound of formula II, the reaction is carried out under reflux.
得到式III化合物的反应中,醇类溶剂为甲醇、乙醇、异丙醇。优选为乙醇。In the reaction to obtain the compound of formula III, the alcoholic solvent is methanol, ethanol, isopropanol. Ethanol is preferred.
得到式III化合物的反应中,硼氢化物为硼氢化钠、硼氢化钾。优选硼氢化钟。In the reaction to obtain the compound of formula III, borohydride is sodium borohydride, potassium borohydride. Preference is given to potassium borohydride.
得到式I化合物的反应中,醇类溶剂为乙醇、异丙醇、正丁醇、异丁醇、正戊醇、异戊醇。优选正丁醇。In the reaction to obtain the compound of formula I, the alcoholic solvent is ethanol, isopropanol, n-butanol, isobutanol, n-amyl alcohol, isoamyl alcohol. Preference is given to n-butanol.
得到式I化合物的反应中,原料和醇的体积比范围为1∶10~40。优选为1∶20~30。In the reaction to obtain the compound of formula I, the volume ratio of the raw material and the alcohol ranges from 1:10 to 40. Preferably it is 1:20-30.
得到式I化合物的反应中,所使用的还原剂为金属钠。In the reaction to obtain the compound of formula I, the reducing agent used is sodium metal.
向三甲氨基哌啶的醇溶液中通干燥氯化氢或者向三甲氨基哌啶水溶液中滴加3mol/l盐酸水溶液,经处理得到三甲氨基哌啶双盐酸盐。三甲氨基哌啶和其他各种酸结合得到各种盐,如双盐酸盐、草酸盐、苦味酸盐。Pass dry hydrogen chloride into the alcohol solution of trimethylaminopiperidine or add 3 mol/l hydrochloric acid aqueous solution dropwise into the aqueous solution of trimethylaminopiperidine to obtain trimethylaminopiperidine dihydrochloride after treatment. Trimethylaminopiperidine is combined with various other acids to obtain various salts, such as bishydrochloride, oxalate, and picrate.
本发明的优点如下:The advantages of the present invention are as follows:
为了降低巴洛沙星原料药的生产成本,使其成为价格上可接受的药物,申请人对3-甲氨基哌啶的合成进行了研究,提出了新的合成路线。本发明大大缩短了反应步骤,路线中所用的原料及试剂均价廉易得,显著降低了3-甲氨基哌啶的生产成本,简化了工艺操作。In order to reduce the production cost of baloxacin bulk drug and make it an acceptable price drug, the applicant has conducted research on the synthesis of 3-methylaminopiperidine and proposed a new synthetic route. The invention greatly shortens the reaction steps, the raw materials and reagents used in the route are cheap and easy to obtain, significantly reduces the production cost of 3-methylaminopiperidine, and simplifies the process operation.
附图说明Description of drawings
图1是本发明的核磁共振谱图。Fig. 1 is the nuclear magnetic resonance spectrogram of the present invention.
图2是本发明的质谱图。Fig. 2 is the mass spectrogram of the present invention.
具体实施方式Detailed ways
实施例1Example 1
在250ml三口烧瓶中,加18.8g(0.2mol)3-氨基吡啶、220ml(2mol)原甲酸三甲酯,搅拌回流10h。反应结束后,减压蒸除溶剂。残余物减压分馏,收集58~60℃/100Pa馏分,得式II化合物(R1为甲基)无色液体20.4g(0.15mol),收率75%。TLC法跟踪反应进程,展开剂为乙酸乙酯,在254nm荧光灯下观察,产物斑点Rf=0.8。In a 250ml three-necked flask, add 18.8g (0.2mol) of 3-aminopyridine and 220ml (2mol) of trimethyl orthoformate, and stir and reflux for 10h. After the reaction, the solvent was distilled off under reduced pressure. The residue was subjected to fractional distillation under reduced pressure, and fractions at 58-60°C/100Pa were collected to obtain 20.4 g (0.15 mol) of the compound of formula II (R 1 is methyl) as a colorless liquid, with a yield of 75%. The progress of the reaction was tracked by TLC, the developer was ethyl acetate, and observed under a 254 nm fluorescent lamp, the product spot R f =0.8.
实施例2Example 2
在250ml三口烧瓶中,加入18.8g(0.2mol)3-氨基吡啶、160ml(1.22mol)原甲酸三乙酯,搅拌回流5h。反应结束后,减压蒸除溶剂。残余物减压分馏,收集60~62℃/100Pa馏分,得式II化合物(R1为乙基)无色液体25.5g(0.17mol),收率85%。TLC法跟踪反应进程,展开剂为乙酸乙酯,在254nm荧光灯下观察,产物斑点Rf=0.8。In a 250ml three-neck flask, add 18.8g (0.2mol) of 3-aminopyridine and 160ml (1.22mol) of triethyl orthoformate, and stir and reflux for 5h. After the reaction, the solvent was distilled off under reduced pressure. The residue was subjected to fractional distillation under reduced pressure, and fractions at 60-62°C/100Pa were collected to obtain 25.5 g (0.17 mol) of the compound of formula II (R 1 is ethyl) as a colorless liquid, with a yield of 85%. The progress of the reaction was tracked by TLC, the developer was ethyl acetate, and observed under a 254 nm fluorescent lamp, the product spot R f =0.8.
实施例3Example 3
在250ml三口烧瓶中,加入18.8g(0.2mol)3-氨基吡啶、40ml(0.3mol)原甲酸三乙酯,搅拌回流6h。反应结束后,减压蒸除溶剂。残余物减压分馏,收集60~62℃/100Pa馏分,得式II化合物(R1为乙基)无色液体18g,收率60%。In a 250ml three-necked flask, add 18.8g (0.2mol) of 3-aminopyridine and 40ml (0.3mol) of triethyl orthoformate, and stir and reflux for 6h. After the reaction, the solvent was distilled off under reduced pressure. The residue was subjected to fractional distillation under reduced pressure, and fractions at 60-62°C/100Pa were collected to obtain 18 g of the compound of formula II (R 1 is ethyl) as a colorless liquid, with a yield of 60%.
实施例4Example 4
取式II化合物(R1为乙基)50g(0.33mol)加入500ml三口烧瓶中,再向其中加入300ml无水乙醇,冰水冷却至0℃,搅拌下分次少量加入15g硼氢化钠,再缓慢升至室温,半小时后缓慢升温至回流。继续反应3h。反应结束后,减压蒸除溶剂。残余物溶于300ml水中,用1000ml乙醚分两次萃取,合并萃取相,无水硫酸镁干燥。回收溶剂,残余物减压分馏,收集80~82℃/100Pa馏分,得3-甲氨基吡啶无色液体28.8g(0.27mol)。TLC法跟踪反应进程,展开剂为乙酸乙酯,在254nm荧光灯下观察,产物斑点Rf=0.5。收率:80%。Take 50 g (0.33 mol) of the compound of formula II (R 1 is ethyl) and add it to a 500 ml three-necked flask, then add 300 ml of absolute ethanol to it, cool to 0° C. with ice water, add 15 g of sodium borohydride in small amounts under stirring, and then Slowly warm to room temperature, then slowly warm to reflux after half an hour. Continue to react for 3h. After the reaction, the solvent was distilled off under reduced pressure. The residue was dissolved in 300ml of water, extracted twice with 1000ml of ether, the extracts were combined and dried over anhydrous magnesium sulfate. The solvent was recovered, the residue was fractionally distilled under reduced pressure, and the 80-82°C/100Pa fraction was collected to obtain 28.8g (0.27mol) of 3-methylaminopyridine as a colorless liquid. The progress of the reaction was tracked by TLC, the developer was ethyl acetate, and observed under a 254 nm fluorescent lamp, the product spot R f =0.5. Yield: 80%.
实施例5Example 5
取式II化合物(R1为乙基)50g(0.33mol)加入500ml三口烧瓶中,再向其中加入300ml无水乙醇,搅拌下分次少量加入20g硼氢化钾,升温至回流。继续反应3h。反应结束后,减压蒸除溶剂。残余物溶于300ml水中,用1000ml乙醚分两次萃取,合并萃取相,无水硫酸镁干燥。回收溶剂,残余物减压分馏,收集80~82℃/100Pa馏分,得3-甲氨基吡啶无色液体29g(0.27mol)。收率:80%。Take 50 g (0.33 mol) of the compound of formula II (R 1 is ethyl) and add it to a 500 ml three-necked flask, then add 300 ml of absolute ethanol therein, add 20 g of potassium borohydride in small amounts under stirring, and heat up to reflux. Continue to react for 3h. After the reaction, the solvent was distilled off under reduced pressure. The residue was dissolved in 300ml of water, extracted twice with 1000ml of ether, the extracts were combined and dried over anhydrous magnesium sulfate. The solvent was recovered, the residue was subjected to fractional distillation under reduced pressure, and the 80-82°C/100Pa fraction was collected to obtain 29 g (0.27 mol) of 3-methylaminopyridine as a colorless liquid. Yield: 80%.
实施例6Example 6
取式II化合物(R1为乙基)50g(0.33mol)加入500ml三口烧瓶中,再向其中加入300ml异丙醇,搅拌下分次少量加入20g硼氢化钠,升温至回流。继续反应5h。反应结束后,减压蒸除溶剂。残余物溶于300ml水中,用1000ml乙醚分两次萃取,合并萃取相,无水硫酸镁干燥。回收溶剂,残余物减压分馏,收集80~82℃/100Pa馏分,得3-甲氨基吡啶无色液体20g(0.185mol)。收率:55.6%。Take 50 g (0.33 mol) of the compound of formula II (R 1 is ethyl) and add it to a 500 ml three-necked flask, then add 300 ml of isopropanol to it, add 20 g of sodium borohydride in small portions under stirring, and heat up to reflux. Continue to react for 5h. After the reaction, the solvent was distilled off under reduced pressure. The residue was dissolved in 300ml of water, extracted twice with 1000ml of ether, the extracts were combined and dried over anhydrous magnesium sulfate. The solvent was recovered, the residue was subjected to fractional distillation under reduced pressure, and the 80-82°C/100Pa fraction was collected to obtain 20 g (0.185 mol) of 3-methylaminopyridine as a colorless liquid. Yield: 55.6%.
实施例7Example 7
在100ml三口烧瓶中,加入1g(9.26mmol)3-甲氨基吡啶和25ml正丁醇,搅拌,升温至回流。分次少量加入2g(87.0mmol)金属钠丝。TLC分析原料反应结束后,冷却至室温,加入2ml水。减压蒸干,30ml三氯甲烷萃取,无水硫酸镁干燥。通干燥氯化氢气体,析出的固体在乙醇-乙醚重结晶,得白色粉未状固体3-甲氨基哌啶双盐酸盐650mg(3.48mmol),收率37.6%。熔点:191~193℃。1HNMR(甲醇)d:1.74~2.35(4H,m,4,5-H),2.80(3H,s,CH3),3.05~3.78(5H,m,2,3,6-H),4.87(2H,s,NH)。MS(m/z):114(M+)。纯度99.7%(GC法)。展开剂:3ml甲醇加3滴氨水,产物斑点Rf=0.3。核磁共振谱及质谱见附图1,2。In a 100ml three-neck flask, add 1g (9.26mmol) of 3-methylaminopyridine and 25ml of n-butanol, stir, and heat up to reflux. 2g (87.0mmol) sodium metal wire was added in small portions. TLC analysis of raw materials After the reaction was completed, the mixture was cooled to room temperature, and 2 ml of water was added. Evaporate to dryness under reduced pressure, extract with 30ml chloroform, and dry over anhydrous magnesium sulfate. The hydrogen chloride gas was dried, and the precipitated solid was recrystallized in ethanol-ether to obtain 650 mg (3.48 mmol) of 3-methylaminopiperidine bishydrochloride as a white powder solid, with a yield of 37.6%. Melting point: 191-193°C. 1 HNMR (methanol) d: 1.74-2.35 (4H, m, 4, 5-H), 2.80 (3H, s, CH3), 3.05-3.78 (5H, m, 2, 3, 6-H), 4.87 ( 2H, s, NH). MS (m/z): 114 (M + ). Purity 99.7% (GC method). Developing solvent: 3ml of methanol plus 3 drops of ammonia water, the product spot R f =0.3. Nuclear Magnetic Resonance Spectrum and Mass Spectrum are shown in Figures 1 and 2.
实施例8Example 8
在100ml三口烧瓶中,加入1g(9.26mmol)3-甲氨基吡啶和40ml异戊醇,搅拌,升温至120℃。分次少量加入2g(87.0mmol)金属钠丝。TLC分析原料反应结束后,冷却至室温,加入2ml水。减压蒸干,30ml三氯甲烷萃取,无水硫酸镁干燥。通干燥氯化氢气体,析出的固体在乙醇-乙醚重结晶,得白色粉未状固体3-甲氨基哌啶双盐酸盐670mg(3.58mmol),收率38.7%。In a 100ml three-necked flask, add 1g (9.26mmol) of 3-methylaminopyridine and 40ml of isoamyl alcohol, stir, and heat up to 120°C. 2g (87.0mmol) sodium metal wire was added in small portions. TLC analysis of raw materials After the reaction was completed, the mixture was cooled to room temperature, and 2 ml of water was added. Evaporate to dryness under reduced pressure, extract with 30ml chloroform, and dry over anhydrous magnesium sulfate. The hydrogen chloride gas was dried, and the precipitated solid was recrystallized in ethanol-ether to obtain 670 mg (3.58 mmol) of 3-methylaminopiperidine bishydrochloride as a white powder solid, with a yield of 38.7%.
实施例9Example 9
在100ml三口烧瓶中,加入1g(9.26mmol)3-甲氨基吡啶和10ml乙醇,搅拌,升温至120℃,分次少量加入2g(87.0mmol)金属钠丝。TLC分析原料反应结束后,冷却至室温,加入2ml水。减压蒸干,30ml三氯甲烷萃取,无水硫酸镁干燥。减压回收溶剂,所得油状物在乙醇-乙醚中重结晶得白色固体300mg(2.63mmol),收率28.4%。熔点:188~190℃。展开剂:3ml甲醇加3滴氨水,产物斑点Rf=0.3。In a 100ml three-neck flask, add 1g (9.26mmol) of 3-methylaminopyridine and 10ml of ethanol, stir, raise the temperature to 120°C, and add 2g (87.0mmol) of sodium metal wire in small portions. TLC analysis of raw materials After the reaction was completed, the mixture was cooled to room temperature, and 2 ml of water was added. Evaporate to dryness under reduced pressure, extract with 30ml chloroform, and dry over anhydrous magnesium sulfate. The solvent was recovered under reduced pressure, and the resulting oil was recrystallized in ethanol-ether to obtain 300 mg (2.63 mmol) of a white solid, with a yield of 28.4%. Melting point: 188~190℃. Developing solvent: 3ml of methanol plus 3 drops of ammonia water, the product spot R f =0.3.
Claims (15)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200410065966XA CN1305849C (en) | 2004-12-29 | 2004-12-29 | Method for preparing 3-methylamino piperidine and its salt |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200410065966XA CN1305849C (en) | 2004-12-29 | 2004-12-29 | Method for preparing 3-methylamino piperidine and its salt |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1660809A CN1660809A (en) | 2005-08-31 |
| CN1305849C true CN1305849C (en) | 2007-03-21 |
Family
ID=35010409
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB200410065966XA Expired - Lifetime CN1305849C (en) | 2004-12-29 | 2004-12-29 | Method for preparing 3-methylamino piperidine and its salt |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1305849C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109503462B (en) * | 2019-01-21 | 2022-03-25 | 内蒙古京东药业有限公司 | Synthesis method of tofacitinib intermediate (3R, 4R) -N, 4-dimethyl-1-benzyl-3-piperidylamine |
| CN113234012B (en) * | 2021-06-01 | 2023-04-25 | 上海巽田科技股份有限公司 | Preparation method of 3-methylaminopyridine and derivative or salt thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1037335A (en) * | 1988-03-11 | 1989-11-22 | 拜尔公司 | Preparation method of 1-cyclopropylquinolone hydroxy acid and derivatives thereof |
| WO2001062734A1 (en) * | 2000-02-25 | 2001-08-30 | Daiichi Pharmaceutical Co., Ltd. | Process for producing quinolonecarboxylic acids and intermediates thereof |
-
2004
- 2004-12-29 CN CNB200410065966XA patent/CN1305849C/en not_active Expired - Lifetime
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1037335A (en) * | 1988-03-11 | 1989-11-22 | 拜尔公司 | Preparation method of 1-cyclopropylquinolone hydroxy acid and derivatives thereof |
| WO2001062734A1 (en) * | 2000-02-25 | 2001-08-30 | Daiichi Pharmaceutical Co., Ltd. | Process for producing quinolonecarboxylic acids and intermediates thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1660809A (en) | 2005-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8754225B2 (en) | Process for preparing a biphenyl-2-ylcarbamic acid | |
| CN1681814A (en) | Preparation of 1H-imidazo [4,5-C] quinolin-4-amines via 1H-imidazo [4,5-C] quinolin-4-phthalimide intermediates | |
| JPH11507379A (en) | N-substituted piperazine nonoate | |
| JP2021513996A (en) | Indane-amine as a PD-L1 antagonist | |
| JP4966314B2 (en) | Methods and intermediates for the synthesis of caspofungin | |
| CA2998875C (en) | Carborane compounds and methods of use thereof | |
| CN102036986A (en) | Conversion of tryptophan into beta-carboline derivatives | |
| CN1305849C (en) | Method for preparing 3-methylamino piperidine and its salt | |
| CZ181891A3 (en) | Hexahydroazepine derivatives | |
| JP2016540801A (en) | Fluorophenylpyrazole compounds | |
| CN105646285A (en) | Vilanterol intermediate, preparation method and application thereof | |
| US20100036125A1 (en) | Synthesis of ccr5 receptor antagonists | |
| CN103613568A (en) | Preparation method of naphthonone and analogues thereof | |
| US10406126B2 (en) | ALDH2 activator | |
| CN107641097A (en) | Piperazine Ma Selin preparation method | |
| CN1066066A (en) | 2-aminopyrimidine-4-carboxamides derivatives, its synthetic method and application aspect medical | |
| CN105348279B (en) | A kind of R-2,2-di(2-thienyl)-2-glycolic acid quinine-3-yl ester and its preparation and application | |
| US20140081020A1 (en) | Methods of producing molindone and its salts | |
| CN106084068B (en) | A Group of Enterobactin-Antibiotic Derivatives and Their Applications | |
| CN1680328A (en) | A kind of preparation method of aripiprazole | |
| CN105440030B (en) | A kind of choline M receptor antagonist aclidinium bromide and preparation method thereof | |
| CN111533706A (en) | A kind of preparation method of 1,4,6-tri-substituted 1,2-dihydro-triazine compounds | |
| CN100402508C (en) | Alkoxy-(tetrazol-1-yl)benzaldehyde compound and production method thereof | |
| JP2003505468A (en) | Novel cyclohexapeptide compounds, their production process and their use as pharmaceuticals | |
| CN114105961B (en) | Preparation method of an IDO1 inhibitor (LY-3381916) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: LIANYUNGANG RUIZHONG PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: JIANGSU ZHENGDA TIANQING PHARMACEUTICAL CO., LTD. Effective date: 20110324 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 222006 NO. 8, JULONG NORTH ROAD, XINPU DISTRICT, LIANYUNGANG CITY, JIANGSU PROVINCE TO: 222006 NO. 16, JINQIAO ROAD, DAPU INDUSTRIAL ZONE, LIANYUNGANG ECONOMIC AND TECHNOLOGICAL DEVELOPMENT ZONE, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20110324 Address after: 222006, Jiangsu Province Economic and Technological Development Zone of Lianyungang Industrial Zone Dapu Road No. 16 Patentee after: LIANYUNGANG RUNZHONG PHARMACEUTICAL Co.,Ltd. Address before: 222006 Sinpo City, Lianyungang Province, North Road, No. 8, No. Patentee before: JIANGSU CHIATAI TIANQING PHARMACEUTICAL Co.,Ltd. |
|
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20070321 |